Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Keverprazan Hydrochloride Tablets

Keplasma Hydrochloride Tablets (trade name: Bewin [3]) is a potassium ion competitive acid blocker (P-CAB) [6-7] jointly developed by Fosun Pharma and Kefopex Pharmaceuticals and exclusively commercialized by Fosun Pharma. It is suitable for the treatment of duodenal ulcers and reflux esophagitis.
On February 15, 2023 [2], the National Medical Products Administration approved Keplasma Hydrochloride Tablets for marketing. [1]